Literature DB >> 28464417

A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Long-Term Comparative Study.

Tomas Uher1, Jan Krasensky2, Manuela Vaneckova2, Lukas Sobisek3, Zdenek Seidl2, Eva Havrdova1, Niels Bergsland4,5, Michael G Dwyer4, Dana Horakova1, Robert Zivadinov4,6.   

Abstract

BACKGROUND AND
PURPOSE: Lesion burden and brain volume changes are frequent end points in research but nowadays are becoming important in the clinical practice of multiple sclerosis (MS). The objective of this study was to investigate the correlation between magnetic resonance imaging (MRI) measures obtained by in-house developed ScanView software and commonly used volumetric techniques for assessment of T2 lesion and whole brain volumes and their changes.
METHODS: Together 3,340 MRI scans from 209 patients after first demyelinating event suggestive of MS, 181 relapsing-remitting MS patients and 43 controls were analyzed. The average number of MRI scans and follow-up duration was 8.2 and 6.5 years, respectively. All MRI scans were performed in a single center but independently analyzed in two neuroimaging centers. Volumetric analysis by ScanView software was applied in Prague. Commonly used techniques, such as SIENA, SIENAX, and Jim software, were applied in Buffalo. Correlations between MRI measures were evaluated using correlation coefficients. Intraindividual variability of longitudinal MRI data was estimated by mean squared error.
RESULTS: The associations of the cross-sectional and longitudinal MRI measures between commonly used techniques and ScanView were significant (r/rho = .83-.95). The associations of cross-sectional MRI measures were stronger (r/rho = .90-.95) compared with longitudinal ones (r = .83). Standardized intraindividual variability of whole brain % volume change was greater in ScanView compared with SIENA (mean squared error .32 vs. .21; P < .001).
CONCLUSIONS: We found relatively strong correlations of cross-sectional and longitudinal data obtained by both techniques. However, SIENA showed lower intraindividual variability than the ScanView method in measuring whole brain volume loss over time.
Copyright © 2017 by the American Society of Neuroimaging.

Entities:  

Keywords:  MRI; T2 lesion volume; brain atrophy; multiple sclerosis; volumetry

Mesh:

Substances:

Year:  2017        PMID: 28464417     DOI: 10.1111/jon.12445

Source DB:  PubMed          Journal:  J Neuroimaging        ISSN: 1051-2284            Impact factor:   2.486


  7 in total

1.  Monocyte NOTCH2 expression predicts IFN-β immunogenicity in multiple sclerosis patients.

Authors:  Marsilio Adriani; Petra Nytrova; Cyprien Mbogning; Signe Hässler; Karel Medek; Poul Erik H Jensen; Paul Creeke; Clemens Warnke; Kathleen Ingenhoven; Bernhard Hemmer; Claudia Sievers; Raija Lp Lindberg Gasser; Nicolas Fissolo; Florian Deisenhammer; Zsolt Bocskei; Vincent Mikol; Anna Fogdell-Hahn; Eva Kubala Havrdova; Philippe Broët; Pierre Dönnes; Claudia Mauri; Elizabeth C Jury
Journal:  JCI Insight       Date:  2018-06-07

2.  Brainstem lesions are associated with diffuse spinal cord involvement in early multiple sclerosis.

Authors:  Michaela Andelova; Karolina Vodehnalova; Jan Krasensky; Eliska Hardubejova; Tereza Hrnciarova; Barbora Srpova; Tomas Uher; Ingrid Menkyova; Dominika Stastna; Lucie Friedova; Jiri Motyl; Jana Lizrova Preiningerova; Eva Kubala Havrdova; Bénédicte Maréchal; Mário João Fartaria; Tobias Kober; Dana Horakova; Manuela Vaneckova
Journal:  BMC Neurol       Date:  2022-07-19       Impact factor: 2.903

3.  Whole brain and deep gray matter atrophy detection over 5 years with 3T MRI in multiple sclerosis using a variety of automated segmentation pipelines.

Authors:  Renxin Chu; Gloria Kim; Shahamat Tauhid; Fariha Khalid; Brian C Healy; Rohit Bakshi
Journal:  PLoS One       Date:  2018-11-08       Impact factor: 3.240

4.  Additive Effect of Spinal Cord Volume, Diffuse and Focal Cord Pathology on Disability in Multiple Sclerosis.

Authors:  Michaela Andelova; Tomas Uher; Jan Krasensky; Lukas Sobisek; Eliska Kusova; Barbora Srpova; Karolina Vodehnalova; Lucie Friedova; Jiri Motyl; Jana Lizrova Preiningerova; Eva Kubala Havrdova; Dana Horakova; Manuela Vaneckova
Journal:  Front Neurol       Date:  2019-08-06       Impact factor: 4.003

5.  Cognitive clinico-radiological paradox in early stages of multiple sclerosis.

Authors:  Tomas Uher; Jan Krasensky; Lukas Sobisek; Jana Blahova Dusankova; Zdenek Seidl; Eva Kubala Havrdova; Maria Pia Sormani; Dana Horakova; Tomas Kalincik; Manuela Vaneckova
Journal:  Ann Clin Transl Neurol       Date:  2017-12-15       Impact factor: 4.511

6.  Isolated Cognitive Decline in Neurologically Stable Patients with Multiple Sclerosis.

Authors:  Jiri Motyl; Lucie Friedova; Manuela Vaneckova; Jan Krasensky; Balazs Lorincz; Jana Blahova Dusankova; Michaela Andelova; Tom A Fuchs; Eva Kubala Havrdova; Ralph H B Benedict; Dana Horakova; Tomas Uher
Journal:  Diagnostics (Basel)       Date:  2021-03-07

7.  Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis.

Authors:  Ranjani Ganapathy Subramanian; Dana Horakova; Manuela Vaneckova; Balazs Lorincz; Jan Krasensky; Eva Kubala Havrdova; Tomas Uher
Journal:  Diagnostics (Basel)       Date:  2021-11-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.